Trade mark rectification for pharmaceutical marks turns on whole-mark comparison, label protection and consumer confusion.

Section 124 of the Trade Marks Act was treated as enabling rather than a strict pre-condition, so rectification remained maintainable despite the absence of prior court permission. A registered label mark was held to extend protection to the word element contained in it, rejecting the argument that the word mark stood outside registration. Comparing FORZID and ORZID as a whole under the anti-dissection rule and the stricter standard for pharmaceutical goods, the court found the marks deceptively similar because the overall visual, structural and phonetic resemblance was likely to confuse consumers and pose health risks. The rectification and removal of the later mark were therefore sustained.

---

---

Issues: (i) Whether rectification proceedings were maintainable without obtaining prior permission of the court under Section 124(1)(b)(ii) of the Trade Marks Act, 1999; (ii) whether registration of a label mark protected the word mark contained in it; (iii) whether the rival marks FORZID and ORZID were deceptively similar so as to justify rectification and removal of the appellant's mark.

Issue (i): Whether rectification proceedings were maintainable without obtaining prior permission of the court under Section 124(1)(b)(ii) of the Trade Marks Act, 1999.

Analysis: The statutory scheme of Section 124 was examined in the context of pending infringement proceedings and the requirement of stay when validity is questioned. Although one view treated prior prima facie satisfaction of the court as necessary before moving rectification, the other view treated the provision as enabling and not a pre-condition to filing. On the facts, the suit was pending in the Madras High Court, and insistence on a prior application there would have been an empty formality because that court had taken the contrary view. The challenge to maintainability was also not pressed at the final hearing before the Single Judge.

Conclusion: The rectification application was held maintainable and the objection based on absence of prior permission failed.

Issue (ii): Whether registration of a label mark protected the word mark contained in it.

Analysis: Section 17 was applied on the footing that a trade mark registered as a whole protects the composite mark, but the essential feature contained in the mark is not denuded of protection merely because the registration is for a label form. The word element within the registered label was treated as part of the protected mark, and the attempt to claim that the opponent had no right to rely on the word mark was rejected.

Conclusion: The registered label mark was held to extend protection to the word element ORZID, and the appellant's objection was rejected.

Issue (iii): Whether the rival marks FORZID and ORZID were deceptively similar so as to justify rectification and removal of the appellant's mark.

Analysis: The competing marks were compared as a whole, applying the anti-dissection rule and the stricter standard used for pharmaceutical goods. The addition of a soft prefix letter was found insufficient to distinguish the marks because the overall visual, structural, and phonetic resemblance remained close. Since the goods were prescription medicines, the possibility of confusion carried serious health consequences, and the use of a similar mark was also found to be tainted by lack of bona fides and a false claim of user.

Conclusion: The marks were held deceptively similar, the appellant's mark was liable to rectification, and the challenge to that finding failed.

Final Conclusion: The appellate challenge did not succeed, and the orders upholding rectification and removal of the appellant's trade mark were sustained.

Ratio Decidendi: In disputes involving pharmaceutical marks, a registered label mark may protect the word element contained within it, and a rival mark must be assessed as a whole under the anti-dissection rule; where the overall similarity is likely to confuse consumers and affect health, rectification is warranted.

---